Nowadays, immunotherapies based on T cells are becoming a huge trend in the treatment of various diseases including Listeria monocytogenes (L. monocytogenes) infections. Among the various solutions emerging, there is a wave of research focusing on γδ T cells. Creative Biolabs has developed a proprietary and robust process to activate and expand different subsets of γδ T cells to numbers sufficient for utilization in the pre-clinical setting. By using γδ T cells, our technology addresses the challenges that immunotherapies face when targeting L. monocytogenes infection. We also engineer γδ T cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to enable the precise engagement and killing of infected cells.